Clinical trial · Interventional
Identifying MSI Status From ctDNA in Chinese Patients With Refractory Advanced Solid Tumors
Identifying Microsatellite Instability Status From Circulating Tumor DNA in Chinese Patients With Refractory Advanced Solid Tumors: a Large Molecular Epidemiological Investigation
NCT03596593CI-TRIAL-00033928IMPACTunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a molecular epidemiological investigation aiming to identify microsatellite instability status from circulating tumor DNA in Chinese patients with refractory advanced solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SPANOM (identifying MSI status from ctDNA) | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Experimental group
- description
- A total of 8-10 mL of blood will be collected from this group of patients and used for blood-MSI testing.
- interventionNames
- Diagnostic Test: SPANOM (identifying MSI status from ctDNA)
Primary outcomes (1)
- measure
- Incidence of MSI-H across different cancer types in Chinese patients
- timeFrame
- Two years
Secondary outcomes (2)
- measure
- Incidence of Lynch syndrome across different cancer types
- timeFrame
- Two years
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male or female, age≥18 years old. 2. Confirmed malignant solid tumor by histopathology or cytopathology. 3. Colorectal cancer: progression after second-line therapy. Non-colorectal cancer: progression after first-line therapy. 4. Time duration from the last time of anti-cancer treatment to blood sample collection for MSI testing ≥ two weeks or five times half-life period of anti-cancer drugs 5. Signed the informed consent with name and time. Exclusion Criteria: 1. Hematological malignancy 2. Patients who received immuotherapies. 3. Patients who received blood transfusion within one month before blood collection. 4. Pregnancy.
References
Publications (1)
- BACKGROUNDZhenghang Wang, Hao Qin, Mei Wang, et al. SPANOM: A cost-effective method of detecting MSI in ctDNA. ASCO 2018, abstract e24263.